Therefore, inhibiting TLR4-NF-κB-mediated release of pro-inflammatory cytokines caused by microglial activation would be an effective therapeutic approach to prevent the apoptotic RGCs in glaucoma. This evidence concerns the gene NFKB1 and glaucoma.